| Followers | 42 |
| Posts | 4316 |
| Boards Moderated | 0 |
| Alias Born | 07/14/2010 |
Wednesday, August 11, 2021 12:29:10 PM
B. Wriley Price target $27.00. Price Per Share PPS is $47.00. Only $20.00 to drop to hit raised price target.
Recent ARCT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:14:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:08:19 PM
- Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress • Business Wire • 05/07/2026 08:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/07/2026 07:37:51 PM
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 • Business Wire • 04/27/2026 08:01:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:05:10 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • InvestorsHub NewsWire • 04/20/2026 01:00:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/26/2026 07:56:44 PM
- Arcturus Therapeutics to Attend Upcoming Investor Conference • Business Wire • 03/05/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:05:54 PM
- Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress • Business Wire • 03/03/2026 09:01:00 PM
- Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 • Business Wire • 02/17/2026 09:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/03/2026 04:27:14 PM
- Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference • Business Wire • 01/08/2026 10:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/30/2025 09:00:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2025 01:30:40 PM
- Arcturus Therapeutics to Attend Upcoming Investor Conference • Business Wire • 11/24/2025 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:25:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 09:09:10 PM
- Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress • Business Wire • 11/10/2025 09:01:00 PM
- Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm • PR Newswire (US) • 11/10/2025 07:40:00 PM
- Arcturus Therapeutics to Attend Upcoming Investor Conferences • Business Wire • 11/04/2025 09:01:00 PM
- Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025 • Business Wire • 10/28/2025 08:01:00 PM
